TNMTumorClassification-v1.0(2020EN) - Bewerkingsoverzicht

Albert-Jan Spruyt: /* Instructions */

2020-09-29T20:43:49Z

‎Instructions

Albert-Jan Spruyt: /* Instructions */

2020-09-29T20:43:29Z

‎Instructions

Albert-Jan Spruyt: /* Instructions */

2020-09-29T20:43:14Z

‎Instructions

Update bot op 29 sep 2020 om 20:19

2020-09-29T20:19:41Z

Albert-Jan Spruyt: /* Instructions */

2020-09-25T20:36:11Z

‎Instructions

Update bot op 25 sep 2020 om 20:22

2020-09-25T20:22:35Z

Wijzigingen bekijken

Update bot op 19 sep 2020 om 19:16

2020-09-19T19:16:25Z

Albert-Jan Spruyt: /* Instructions */

2020-09-09T21:06:31Z

‎Instructions

Albert-Jan Spruyt: /* Instructions */

2020-09-09T21:02:09Z

‎Instructions

Update bot op 9 sep 2020 om 20:25

2020-09-09T20:25:26Z

@@ Regel 760: / Regel 760: @@
 Development or implementation of a tumor-specific information model of the TNM Classification standard requires insight into how values sets can be restricted, expanded, and applied.<BR>
 Restriction of a value list means either leaving out items or making items more specific by choosing other terms within the official code system. The aim for the future is to have available ready-to-use value sets per type of malignancy.<BR>
-<b>Codes systems</b>
+<b>Codes systems</b><br>
 This clinical model uses 2 international code systems:<BR>
 <ul>

@@ Regel 757: / Regel 757: @@
 ==Instructions==
-<b>From a generic TNM Classification towards a disease-specific TNM Classification</b>
+<b>From a generic TNM Classification towards a disease-specific TNM Classification</b><br>
 Development or implementation of a tumor-specific information model of the TNM Classification standard requires insight into how values sets can be restricted, expanded, and applied.<BR>
 Restriction of a value list means either leaving out items or making items more specific by choosing other terms within the official code system. The aim for the future is to have available ready-to-use value sets per type of malignancy.<BR>

@@ Regel 773: / Regel 773: @@
 	<li>In case of multiple primary tumors in the same organ, one should classify the tumor with the highest T-category, and mention the multiple presence or number of tumors between brackets. For example: T2 (m) or T2 (5). The lesion with the highest T-category determines the classification of the tumor. In order to distinguish between lesions and to represent each individual lesion, the HCIM has the container ‘Lesion’. Each lesion has a number. The HCIM does not represent which lesion (e.g. 1, 2, or 4) has the highest T-category, since this is only clear after judgment by the health professional on the basis of morphology and/or imaging.</li>
 </ul>
-<b>Use of the </b><b><u>UICC (</u></b><a href="$inet://http://www.uicc.org/resources/tnm"><font color="#0000ff"><b><u>http://www.uicc.org/resources/tnm</u></b></font></a><b><u>) </u></b><b>/ </b><b><u>AJCC (</u></b><a href="$inet://http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx"><font color="#0000ff"><b><u>http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx</u></b></font></a><b><u> )</u></b><b> version of the TNM Classification of Malignant Tumours.</b>
+<b>Use of the [http://www.uicc.org/resources/tnm UICC] / [http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx AJCC] version of the TNM Classification of Malignant Tumours.</b>
 <ul>
 	<li>Although definitions and wording should not differ between the AJCC and UICC TNM classifications, some differences have regrettably crept in (for example: the definition of regional lymph nodes associated with carcinomas of the esophagus and endometrium). Therefore, the HCIM allows for choosing between the UICC or AJCC version. Criteria within the TNM-classification system have changed over the years and resulted in various editions. As a result, a specific tumor stage may have a completely different prognosis, depending on the edition used. Furthermore, it is important to consider the consequences of improved treatment over time.</li>

@@ Regel 202: / Regel 202: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=277208005 277208005] M category</span>
+|<span title = "Codesystem: SNOMED CT; M-categorie van Tumor-Node-Metastasis-classificatie (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=277208005 277208005] M category</span>
 |}
+|
@@ Regel 224: / Regel 224: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=385421009 385421009] Site of distant metastasis</span>
+|<span title = "Codesystem: SNOMED CT; Locatie van metastase op afstand (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=385421009 385421009] Site of distant metastasis</span>
 |}
+|
@@ Regel 239: / Regel 239: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=385421009 385421009] Site of distant metastasis</span>
+|<span title = "Codesystem: SNOMED CT; Locatie van metastase op afstand (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=385421009 385421009] Site of distant metastasis</span>
 |}
+|
@@ Regel 270: / Regel 270: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=277206009 277206009] N category</span>
+|<span title = "Codesystem: SNOMED CT; N-categorie van tumor-node-metastasis-classificatie (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=277206009 277206009] N category</span>
 |}
+|
@@ Regel 315: / Regel 315: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=397440000 397440000] Site of involved lymph node</span>
+|<span title = "Codesystem: SNOMED CT; Locatie van aangedane lymfeklier (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=397440000 397440000] Site of involved lymph node</span>
 |}
+|
@@ Regel 346: / Regel 346: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT&#xA;Unknown code" style = "color:red">133641000146103 number of primary tumors</span>
+|<span title = "Codesystem: SNOMED CT; Aantal primaire tumoren (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=133641000146103 133641000146103] Number of primary tumors</span>
 |}
+|
@@ Regel 364: / Regel 364: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=78873005 78873005] T category</span>
+|<span title = "Codesystem: SNOMED CT; T-categorie van Tumor-Node-Metastasis-classificatie (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=78873005 78873005] T category</span>
 |}
+|
@@ Regel 459: / Regel 459: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=399687005 399687005] Primary tumor site</span>
+|<span title = "Codesystem: SNOMED CT; Locatie van primaire tumor (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=399687005 399687005] Primary tumor site</span>
 |}
+|
@@ Regel 475: / Regel 475: @@
 {|
 |-
-|<span title = "Codesystem: SNOMED CT (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=399687005 399687005] Primary tumor site</span>
+|<span title = "Codesystem: SNOMED CT; Locatie van primaire tumor (observable entity)" >[https://terminologie.nictiz.nl/art-decor/snomed-ct?conceptId=399687005 399687005] Primary tumor site</span>
 |}
+|
@@ Regel 773: / Regel 773: @@
 	<li>In case of multiple primary tumors in the same organ, one should classify the tumor with the highest T-category, and mention the multiple presence or number of tumors between brackets. For example: T2 (m) or T2 (5). The lesion with the highest T-category determines the classification of the tumor. In order to distinguish between lesions and to represent each individual lesion, the HCIM has the container ‘Lesion’. Each lesion has a number. The HCIM does not represent which lesion (e.g. 1, 2, or 4) has the highest T-category, since this is only clear after judgment by the health professional on the basis of morphology and/or imaging.</li>
 </ul>
-<b>Use of the [http://www.uicc.org/resources/tnm UICC] / [http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx AJCC]( version of the TNM Classification of Malignant Tumours.</b>
+<b>Use of the </b><b><u>UICC (</u></b><a href="$inet://http://www.uicc.org/resources/tnm"><font color="#0000ff"><b><u>http://www.uicc.org/resources/tnm</u></b></font></a><b><u>) </u></b><b>/ </b><b><u>AJCC (</u></b><a href="$inet://http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx"><font color="#0000ff"><b><u>http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx</u></b></font></a><b><u> )</u></b><b> version of the TNM Classification of Malignant Tumours.</b>
 <ul>
 	<li>Although definitions and wording should not differ between the AJCC and UICC TNM classifications, some differences have regrettably crept in (for example: the definition of regional lymph nodes associated with carcinomas of the esophagus and endometrium). Therefore, the HCIM allows for choosing between the UICC or AJCC version. Criteria within the TNM-classification system have changed over the years and resulted in various editions. As a result, a specific tumor stage may have a completely different prognosis, depending on the edition used. Furthermore, it is important to consider the consequences of improved treatment over time.</li>
@@ Regel 6.253: / Regel 6.253: @@
 SNOMED CT and LOINC codes are based on:
 <ul>
-<li>SNOMED Clinical Terms version: 20200309 [R] (March 2020 Interim Release)</li>
+<li>SNOMED Clinical Terms version: 20200731 [R] (July 2020 Release)</li>
 <li>LOINC version 2.67</li>
 </ul>
 Conditions for use are located on the mainpage<!--ftConditions--> [[Bestand:list2.png|link=HCIM_Mainpage<!--wikiMainpage-->]]<BR>
-This page is generated on 25/09/2020 22:18:04 with ZibExtraction v. 4.0.7573.39884<!--ftDate--> <BR>
+This page is generated on 29/09/2020 21:24:53 with ZibExtraction v. 4.0.7577.31095<!--ftDate--> <BR>
 -----
 <div style="text-align: right; direction: ltr; margin-left: 1em;" >[[Bestand: Back 16.png| link= HCIM_Release<!--wikiReleasePage-->_2020(EN)]] [[HCIM_Release<!--wikiReleasePage-->_2020(EN) |Back to HCIM list<!--hdBackToMainPage--> ]]</div>

@@ Regel 773: / Regel 773: @@
 	<li>In case of multiple primary tumors in the same organ, one should classify the tumor with the highest T-category, and mention the multiple presence or number of tumors between brackets. For example: T2 (m) or T2 (5). The lesion with the highest T-category determines the classification of the tumor. In order to distinguish between lesions and to represent each individual lesion, the HCIM has the container ‘Lesion’. Each lesion has a number. The HCIM does not represent which lesion (e.g. 1, 2, or 4) has the highest T-category, since this is only clear after judgment by the health professional on the basis of morphology and/or imaging.</li>
 </ul>
-<b>Use of the </b><b><u>UICC (</u></b><a href="$inet://http://www.uicc.org/resources/tnm"><font color="#0000ff"><b><u>http://www.uicc.org/resources/tnm</u></b></font></a><b><u>) </u></b><b>/ </b><b><u>AJCC (</u></b><a href="$inet://http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx"><font color="#0000ff"><b><u>http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx</u></b></font></a><b><u> )</u></b><b> version of the TNM Classification of Malignant Tumours.</b>
+<b>Use of the [http://www.uicc.org/resources/tnm UICC] / [http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx AJCC]( version of the TNM Classification of Malignant Tumours.</b>
 <ul>
 	<li>Although definitions and wording should not differ between the AJCC and UICC TNM classifications, some differences have regrettably crept in (for example: the definition of regional lymph nodes associated with carcinomas of the esophagus and endometrium). Therefore, the HCIM allows for choosing between the UICC or AJCC version. Criteria within the TNM-classification system have changed over the years and resulted in various editions. As a result, a specific tumor stage may have a completely different prognosis, depending on the edition used. Furthermore, it is important to consider the consequences of improved treatment over time.</li>

@@ Regel 124: / Regel 124: @@
 rect 670 103 836 139 [[#ycT_PrimaryTumorCodelist]]
 rect 670 50 836 86 [[#cT_PrimaryTumorCodelist]]
-rect 143 268 316 318 [[#m_NumberOfPrimaryTumors Codelist]]
+rect 141 267 314 317 [[#m_NumberOfPrimaryTumors Codelist]]
 rect 327 740 442 810 [[AnatomicalLocation-v1.0(2020EN)]]
 rect 463 662 667 712 [[#G_HistopathologicalGradingCodelist]]
@@ Regel 773: / Regel 773: @@
 	<li>In case of multiple primary tumors in the same organ, one should classify the tumor with the highest T-category, and mention the multiple presence or number of tumors between brackets. For example: T2 (m) or T2 (5). The lesion with the highest T-category determines the classification of the tumor. In order to distinguish between lesions and to represent each individual lesion, the HCIM has the container ‘Lesion’. Each lesion has a number. The HCIM does not represent which lesion (e.g. 1, 2, or 4) has the highest T-category, since this is only clear after judgment by the health professional on the basis of morphology and/or imaging.</li>
 </ul>
-<b>Use of the [//http://www.uicc.org/resources/tnm UICC] / [//http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx AJCC] version of the TNM Classification of Malignant Tumours.</b>
+<b>Use of the </b><b><u>UICC (</u></b><a href="$inet://http://www.uicc.org/resources/tnm"><font color="#0000ff"><b><u>http://www.uicc.org/resources/tnm</u></b></font></a><b><u>) </u></b><b>/ </b><b><u>AJCC (</u></b><a href="$inet://http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx"><font color="#0000ff"><b><u>http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx</u></b></font></a><b><u> )</u></b><b> version of the TNM Classification of Malignant Tumours.</b>
 <ul>
 	<li>Although definitions and wording should not differ between the AJCC and UICC TNM classifications, some differences have regrettably crept in (for example: the definition of regional lymph nodes associated with carcinomas of the esophagus and endometrium). Therefore, the HCIM allows for choosing between the UICC or AJCC version. Criteria within the TNM-classification system have changed over the years and resulted in various editions. As a result, a specific tumor stage may have a completely different prognosis, depending on the edition used. Furthermore, it is important to consider the consequences of improved treatment over time.</li>
@@ Regel 2.506: / Regel 2.506: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Differentiatiegraad kan niet beoordeeld worden.Grade cannot be assessed.
+|Differentiatiegraad kan niet beoordeeld worden.
 |-style="vertical-align:top; "
 |G1
@@ Regel 2.512: / Regel 2.512: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Goed gedifferentieerd.Well differentiated.
+|Goed gedifferentieerd.
 |-style="vertical-align:top; "
 |G2
@@ Regel 2.518: / Regel 2.518: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Matig gedifferentieerd.Moderately differentiated.
+|Matig gedifferentieerd.
 |-style="vertical-align:top; "
 |G3
@@ Regel 2.524: / Regel 2.524: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Slecht gedifferentieerd.Poorly differentiated.
+|Slecht gedifferentieerd.
 |-style="vertical-align:top; "
 |G3-4
@@ Regel 2.530: / Regel 2.530: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Slecht gedifferentieerd of ongedifferentieerd.poorly differentiated or undifferentiated.
+|Slecht gedifferentieerd of ongedifferentieerd.
 |-style="vertical-align:top; "
 |G4
@@ Regel 2.536: / Regel 2.536: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|Ongedifferentieerd.Undifferentiated.
+|Ongedifferentieerd.
 |-style="vertical-align:top; "
 |G5
@@ Regel 2.542: / Regel 2.542: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|G5
+|Differentiatiegraad groep 5 (Gleason score: 9-10)
 |-style="vertical-align:top; "
 |LowMitoticRate
@@ Regel 2.548: / Regel 2.548: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|LowMitoticRate
+|Lage mitotische rato
 |-style="vertical-align:top; "
 |HighMitoticRate
@@ Regel 2.554: / Regel 2.554: @@
 |G_DifferentiatiegraadTumor
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.5
-|HighMitoticRate
+|Hoge mitotische rato
 |}
 === m_NumberOfPrimaryTumors Codelist===
@@ Regel 2.637: / Regel 2.637: @@
 |Other
 |OTH
-|nullflavor
+|NullFlavor
 |2.16.840.1.113883.5.1008
 |Anders, specificeer.
@@ Regel 6.257: / Regel 6.257: @@
 </ul>
 Conditions for use are located on the mainpage<!--ftConditions--> [[Bestand:list2.png|link=HCIM_Mainpage<!--wikiMainpage-->]]<BR>
-This page is generated on 09/09/2020 22:20:45 with ZibExtraction v. 4.0.7556.18438<!--ftDate--> <BR>
+This page is generated on 19/09/2020 20:59:25 with ZibExtraction v. 4.0.7556.18438<!--ftDate--> <BR>
 -----
 <div style="text-align: right; direction: ltr; margin-left: 1em;" >[[Bestand: Back 16.png| link= HCIM_Release<!--wikiReleasePage-->_2020(EN)]] [[HCIM_Release<!--wikiReleasePage-->_2020(EN) |Back to HCIM list<!--hdBackToMainPage--> ]]</div>

@@ Regel 773: / Regel 773: @@
 	<li>In case of multiple primary tumors in the same organ, one should classify the tumor with the highest T-category, and mention the multiple presence or number of tumors between brackets. For example: T2 (m) or T2 (5). The lesion with the highest T-category determines the classification of the tumor. In order to distinguish between lesions and to represent each individual lesion, the HCIM has the container ‘Lesion’. Each lesion has a number. The HCIM does not represent which lesion (e.g. 1, 2, or 4) has the highest T-category, since this is only clear after judgment by the health professional on the basis of morphology and/or imaging.</li>
 </ul>
-<b>Use of the [http://www.uicc.org/resources/tnm UICC]/[http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx AJCC] version of the TNM Classification of Malignant Tumours.</b>
+<b>Use of the </b><b><u>UICC (</u></b><a href="$inet://http://www.uicc.org/resources/tnm"><font color="#0000ff"><b><u>http://www.uicc.org/resources/tnm</u></b></font></a><b><u>) </u></b><b>/ </b><b><u>AJCC (</u></b><a href="$inet://http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx"><font color="#0000ff"><b><u>http://cancerstaging.org/references-tools/deskreferences/Pages/default.aspx</u></b></font></a><b><u> )</u></b><b> version of the TNM Classification of Malignant Tumours.</b>
 <ul>
 	<li>Although definitions and wording should not differ between the AJCC and UICC TNM classifications, some differences have regrettably crept in (for example: the definition of regional lymph nodes associated with carcinomas of the esophagus and endometrium). Therefore, the HCIM allows for choosing between the UICC or AJCC version. Criteria within the TNM-classification system have changed over the years and resulted in various editions. As a result, a specific tumor stage may have a completely different prognosis, depending on the edition used. Furthermore, it is important to consider the consequences of improved treatment over time.</li>
@@ Regel 2.672: / Regel 2.672: @@
 |PnX
 |Pn_PerineuraleInvasie
-|2.16.840.1.113883.2.4.3.11.60.40.5.1.
+|2.16.840.1.113883.2.4.3.11.60.40.5.1.3
 |Aanwezigheid van Perineurale invasie kan niet beoordeeld worden
 |-style="vertical-align:top; "
@@ Regel 5.010: / Regel 5.010: @@
 |-style="vertical-align:top; "
 |UICC 8e editie
-|UICC TNM8
+|UICCTNM8
 |TNMVersie
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.8
@@ Regel 5.309: / Regel 5.309: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycNX
+|ycN2c(sn)
 |-style="vertical-align:top; "
 |ycN3
@@ Regel 5.315: / Regel 5.315: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycNX(f)
+|ycN3
 |-style="vertical-align:top; "
 |ycN3(f)
@@ Regel 5.321: / Regel 5.321: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycNX(sn)
+|ycN3(f)
 |-style="vertical-align:top; "
 |ycN3(sn)
@@ Regel 5.327: / Regel 5.327: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0
+|ycN3(sn)
 |-style="vertical-align:top; "
 |ycN3a
@@ Regel 5.333: / Regel 5.333: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(f)
+|ycN3a
 |-style="vertical-align:top; "
 |ycN3a(f)
@@ Regel 5.339: / Regel 5.339: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(sn)
+|ycN3a(f)
 |-style="vertical-align:top; "
 |ycN3a(sn)
@@ Regel 5.345: / Regel 5.345: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(i-)
+|ycN3a(sn)
 |-style="vertical-align:top; "
 |ycN3b
@@ Regel 5.351: / Regel 5.351: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(i-)(sn)
+|ycN3b
 |-style="vertical-align:top; "
 |ycN3b(f)
@@ Regel 5.357: / Regel 5.357: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(i+)
+|ycN3b(f)
 |-style="vertical-align:top; "
 |ycN3b(sn)
@@ Regel 5.363: / Regel 5.363: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(i+)(sn)
+|ycN3b(sn)
 |-style="vertical-align:top; "
 |ycN3c
@@ Regel 5.369: / Regel 5.369: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(mol-)
+|ycN3c
 |-style="vertical-align:top; "
 |ycN3c(f)
@@ Regel 5.375: / Regel 5.375: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(mol-)(sn)
+|ycN3c(f)
 |-style="vertical-align:top; "
 |ycN3c(sn)
@@ Regel 5.381: / Regel 5.381: @@
 |N_RegionaleLymfeklieren
 |2.16.840.1.113883.2.4.3.11.60.40.4.10.2
-|ycN0(mol+)
+|ycN3c(sn)
 |}
 Note:<!--vsNotes--> De uitbreiding naar regionale lymfeklieren (N) voor een klinische classificatie uitgevoerd tijdens of na een initiële multimodaliteitsbehandeling (zijnde niet- chirurgisch).
@@ Regel 6.257: / Regel 6.257: @@
 </ul>
 Conditions for use are located on the mainpage<!--ftConditions--> [[Bestand:list2.png|link=HCIM_Mainpage<!--wikiMainpage-->]]<BR>
-This page is generated on 05/09/2020 22:18:39 with ZibExtraction v. 4.0.7553.39553<!--ftDate--> <BR>
+This page is generated on 09/09/2020 22:20:45 with ZibExtraction v. 4.0.7556.18438<!--ftDate--> <BR>
 -----
 <div style="text-align: right; direction: ltr; margin-left: 1em;" >[[Bestand: Back 16.png| link= HCIM_Release<!--wikiReleasePage-->_2020(EN)]] [[HCIM_Release<!--wikiReleasePage-->_2020(EN) |Back to HCIM list<!--hdBackToMainPage--> ]]</div>